Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support

Noel Milpied, Eric Deconinck, Fanny Gaillard, Vincent Delwail, Charles Foussard, Christian Berthou, Remy Gressin, Virginie Lucas, Philippe Colombat, Jean-Luc Harousseau, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang, Noel Milpied, Eric Deconinck, Fanny Gaillard, Vincent Delwail, Charles Foussard, Christian Berthou, Remy Gressin, Virginie Lucas, Philippe Colombat, Jean-Luc Harousseau, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang

Abstract

Background: The efficacy of first-line intensive chemotherapy plus transplantation of autologous hematopoietic stem cells in adults with disseminated aggressive lymphoma is unknown.

Methods: We compared high-dose therapy plus autologous stem-cell support with the standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in a randomized trial. The patients were 15 to 60 years of age, had untreated aggressive lymphoma, and were at low, low intermediate, or high intermediate risk of death (i.e., a maximum of two adverse prognostic factors) according to the age-adjusted International Prognostic Index. The primary outcome was event-free survival at five years.

Results: Of 207 consecutive patients, 197 underwent randomization; 99 were assigned to receive CHOP, and 98 to receive high-dose chemotherapy plus stem-cell transplantation. Overall, 78 percent of the patients completed the assigned treatment; the median follow-up was four years. The estimated event-free survival rate (+/-SD) at five years was significantly higher among patients who received high-dose therapy than among patients who received CHOP (55+/-5 percent vs. 37+/-5 percent, P=0.037). Among patients with a high intermediate risk of death, according to the age-adjusted International Prognostic Index, the five-year survival rate was significantly higher after high-dose therapy than after CHOP (74+/-6 percent vs. 44+/-7 percent, P=0.001).

Conclusions: High-dose chemotherapy with autologous stem-cell support is superior to CHOP in adults with disseminated aggressive lymphoma.

Copyright 2004 Massachusetts Medical Society

Source: PubMed

3
Sottoscrivi